Verici Dx plc

LSE VRCI.L

Verici Dx plc Goodwill for the year ending December 31, 2023

Verici Dx plc Goodwill is NA for the year ending December 31, 2023. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

LSE: VRCI.L

Verici Dx plc

CEO	Ms. Sara jane Barrington A.C.A., A.C.I.M.
IPO Date	Nov. 3, 2020
Location	United Kingdom
Headquarters	Avon House
Employees	19
Sector	Healthcare
Industries Biotechnology Clinical Trials Fintech

Description

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

Key trends

Past 5 years